232 related articles for article (PubMed ID: 28270485)
1. Long-term safety and efficacy of ziv-aflibercept in retinal diseases.
Mansour AM; Ashraf M; Dedhia CJ; Charbaji A; Souka AAR; Chhablani J
Br J Ophthalmol; 2017 Oct; 101(10):1374-1376. PubMed ID: 28270485
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration.
Braimah IZ; Stewart M; Videkar C; Dedhia CJ; Chhablani J;
Br J Ophthalmol; 2017 Sep; 101(9):1201-1205. PubMed ID: 28119292
[TBL] [Abstract][Full Text] [Related]
3. Two-year outcomes of intravitreal ziv-aflibercept.
Mansour AM; Ashraf M; Charbaji A; Younis MH; Souka AA; Dogra A; Mansour HA; Chhablani J;
Br J Ophthalmol; 2018 Oct; 102(10):1387-1390. PubMed ID: 29317400
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy.
Mansour AM; Charbaji A; Farah ME; Mansour HA; Chhablani J
Br J Ophthalmol; 2019 Jul; 103(7):938-941. PubMed ID: 30072436
[TBL] [Abstract][Full Text] [Related]
5. INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.
de Oliveira Dias JR; Costa de Andrade G; Kniggendorf VF; Novais EA; Takahashi VKL; Maia A; Meyer C; Watanabe SES; Farah ME; Rodrigues EB
Retina; 2019 Apr; 39(4):648-655. PubMed ID: 29232334
[TBL] [Abstract][Full Text] [Related]
6. Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema.
Mansour AM; Dedhia C; Chhablani J
Br J Ophthalmol; 2017 Feb; 101(2):166-169. PubMed ID: 27190127
[TBL] [Abstract][Full Text] [Related]
7. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal Ziv-Aflibercept : Safety Analysis in Eyes Receiving More Than Ten Intravitreal Injections.
Singh SR; Chattannavar G; Ayachit A; Pimentel MC; Alfaro A; Tiwari S; Heranjal A; Subramanyam A; Braimah IZ; Dhami A; Sachdev P; Mansour A; Chhablani J
Semin Ophthalmol; 2020 Jan; 35(1):2-6. PubMed ID: 31690175
[No Abstract] [Full Text] [Related]
9. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization.
Wang JK; Huang TL; Chang PY; Chen YT; Chang CW; Chen FT; Hsu YR; Chen YJ
Sci Rep; 2018 Sep; 8(1):14389. PubMed ID: 30258077
[TBL] [Abstract][Full Text] [Related]
11. SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT.
Chhablani J; Narayanan R; Mathai A; Yogi R; Stewart M
Retina; 2016 Jun; 36(6):1126-31. PubMed ID: 26655620
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
[TBL] [Abstract][Full Text] [Related]
13. Initial utilization of aflibercept in exudative age-related macular degeneration.
Cho H; Weber ML; Shah CP; Heier JS
Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352
[TBL] [Abstract][Full Text] [Related]
14. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept for Radiation Maculopathy Study: A Prospective, Randomized Clinical Study.
Murray TG; Latiff A; Villegas VM; Gold AS
Ophthalmol Retina; 2019 Jul; 3(7):561-566. PubMed ID: 31277797
[TBL] [Abstract][Full Text] [Related]
16. Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.
Mansour AM; Chhablani J; Antonios RS; Yogi R; Younis MH; Dakroub R; Chahine H
Br J Ophthalmol; 2016 Dec; 100(12):1629-1633. PubMed ID: 27030277
[TBL] [Abstract][Full Text] [Related]
17. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
Nawar AE; Wasfy T; Shafik HM
BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
[TBL] [Abstract][Full Text] [Related]
18. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
[TBL] [Abstract][Full Text] [Related]
19. Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept.
Hernandez-Da Mota SE; Melo-Granados EAR; Fromow-Guerra J; Bejar-Cornejo F; Gallego-Pinazo R; Rodríguez-Ayala E
Eur J Ophthalmol; 2019 May; 29(3):271-277. PubMed ID: 30841748
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]